Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHCUZV)

Drug Name

SEL120 Drug Info

Synonyms

SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]
Myelodysplastic syndrome	2A37	Phase 1	[1]

Cross-matching ID

PubChem CID: 73776232
CAS Number: CAS 1609452-30-3
TTD Drug ID: DMHCUZV

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cyclin-dependent kinase 8 (CDK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[3]
Macrocycle derivative 14	DMXSRPH	N. A.	N. A.	Patented	[3]
CCT251545	DMNA9KW	Colorectal cancer	2B91.Z	Preclinical	[4]
Oxindole 94	DMPFD6Y	Pain	MG30-MG3Z	Investigative	[5]
Oxindole 16 (compound 3)	DMM5208	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 19 (CDK19)	TTNABU9	CDK19_HUMAN	Inhibitor	[2]
Cyclin-dependent kinase 8 (CDK8)	TTBJR4L	CDK8_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04021368) SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Ryvu Therapeutics.
3	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
4	Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
5	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.